...
首页> 外文期刊>Investigational new drugs. >The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study.
【24h】

The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study.

机译:II期研究:静脉内草酸奥沙利铂和亚叶酸混合化疗以及5-氟尿嘧啶肝内输注对结直肠肝转移患者的疗效:II期研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Intra-arterial chemotherapy in patients with liver metastases from colorectal cancer has some limitations such as hepatic toxicity and extra-hepatic progression. With the aim of overcoming these limitations, a phase II trial was designed to assess the efficacy and tolerability of a hybrid chemotherapy regimen with systemic infusion of oxaliplatin and folinic acid associated with intra-arterial 5-fluorouracil. Thirty-nine patients with colorectal liver metastases were recruited. The median age was 59 years, 30 patients (77%) had synchronous metastases, and half of the patients were chemo-naive. A total of 313 chemotherapy cycles were administered (median number 8). Treatment was well tolerated and hepatic toxicity negligible. Out of 34 evaluable patients an ORR of 41%. was observed. Eight patients (21%) underwent radical liver surgery. The median time to progression (TTP) was 10 months (range 2-63) and the median overall survival (OS) 21 months (range 6-63). Extra-hepatic progression was observed in sixpatients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached.
机译:大肠癌肝转移患者的动脉内化疗有一些局限性,例如肝毒性和肝外进展。为了克服这些局限性,设计了一项II期试验,以评估混合输注奥沙利铂和亚叶酸与动脉内5-氟尿嘧啶相关的混合化疗方案的疗效和耐受性。招募了39例结直肠肝转移患者。中位年龄为59岁,有30例患者(77%)发生同步转移,一半的患者是未经化疗的。总共进行了313个化疗周期(中位数为8)。治疗耐受性良好,肝毒性可忽略不计。在34位可评估患者中,ORR为41%。被观测到。八名患者(21%)接受了根治性肝手术。中位进展时间(TTP)为10个月(范围2-63),中位总生存期(OS)为21个月(范围6-63)。在六名患者中观察到肝外进展。我们的结果表明,即使经常发生技术并发症,该方案也很有效。我们达到了降低肝毒性和肝外进展的目的。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号